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Abstract: Resveratrol, a natural stilbene found in grapes and wines exhibits a wide range 
of pharmacological properties. Resveratrol is also known as a good chemopreventive agent 
for inhibiting carcinogenesis processes that target kinases, cyclooxygenases, ribonucleotide 
reductase and DNA polymerases. A total of 19 analogues with an amide moiety were 
synthesized and the cytotoxic effects of the analogues on a series of human cancer cell 
lines are reported. Three compounds 6d, 6i and 6n showed potent cytotoxicity against 
prostate cancer DU-145 (IC50 = 16.68 µM), colon cancer HT-29 (IC50 = 7.51 µM) and 
breast cancer MCF-7 (IC50 = 21.24 µM), respectively, which are comparable with 
vinblastine. The resveratrol analogues were synthesized using the Heck method. 
Keywords: o-carboxamido stilbenes; amido stilbenes; Heck protocol; cytotoxic effects 
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1. Introduction 
Resveratrol, a popular stilbenoid-type compound exerts a wide range of biological activities, such 
as anti-carcinogenic, antioxidant, anti-inflammatory, anti-tumor [1,2]. Resveratrol is widely found in 
grapes and red wine [3,4], and the amount of resveratrol in the skin of fresh grape is between  
50–100 mg/g [5]. Resveratrol, a resorcinol derivative was first isolated from the Japanese plant 
Veratrum grandiflorum [6] and was reported as a phytoalexin produced by plants in response to 
pathogen attack or environmental pressure such as injuries [7]. Resveratrol is also known as a calorie 
restriction mimetic which is a hypothetical class of drugs that would mimic the substantial anti-aging 
effects caloric restrictions [8]. Resveratrol is commonly connected to the French Paradox i.e.,  
wine-drinking population with high intake of saturated fat but with few heart related problems, which 
is attributed to the inhibition of LDL oxidation in human [9]. In relation to cardiovascular disease, an 
animal model showed that resveratrol reduces blood pressure and cardiac hypertrophy in hypertensive 
animals as well as protects the heart from ischemia-reperfusion injury and slows the progression  
of atherosclerosis [10]. 
The interesting and intriguing biological properties of resveratrol have attracted much attention 
from synthetic chemists which led to the synthesis of numerous analogues containing diverse range of 
functional groups. For instance, pterostilbene which is a simple analogue with two methoxyl groups on 
the aromatic ring have been shown to exhibit good cytotoxicity against estrogen-insensitive breast 
cancer (MDA-MB-231) [11]. Some naphthyl combretastatin analogues have been reported to inhibit 
tubulin polymerization [12]. Similar to the naphthalene moiety, stilbene coumarin analogues showed 
potent antiproliferative activity toward human lung carcinoma cell line (H460) [2]. By substituting the 
hydroxyl group in resveratrol with an aliphatic acid, positive result was seen in inhibiting cell apoptosis 
through Toll-like receptor 2 (TLR2) [13]. Another type of analogue, the benzenesulfonamides having a 
sulfonamide moiety, were tested against 60 human tumor cell lines and were notably cytotoxic toward 
BT-549 breast cancer and HT-29 colon cancer [14]. 
Previously our group has synthesized a nine o-carboxamido stilbene, incorporating the amide 
moiety and exhibiting good biological activity against a colon cell line (HT-29), liver cell line (HEP-G2), 
Jurkat cell and murine leukemic cell line [15–17]. In continuation of this study, we have further 
synthesized more analogues and all these compounds were evaluated for their cytotoxicity against 6 
human cell lines; colon cancer (HT-29), estrogen-sensitive breast cancer (MCF-7), estrogen-insensitive 
breast cancer (MDA-MB-231), prostate cancer (DU-145), pancreatic cancer (BxPC-3) and normal 
pancreatic cells (hTERT-HPNE). A total of 19 o-carboxamido stilbenes were synthesized (6a–6s) 
containing different substituted groups linked to the amide group at ring A (Scheme 1). While at ring B, 
electron donating groups such as methoxy and electron withdrawing group (Cl, Br and F) were 
attached at different positions. 
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Scheme 1. Chemical structures of o-carboxamido stilbene analogues mentioned in this 
study and general structure of the synthesized compounds (6a–6s). 
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2. Results and Discussion 
2.1. Synthesis of o-Carboxamido Stilbene 
The synthesis of o-carboxamido stilbenes have been described in Scheme 2. Substituted 
benzaldehydes 2a–2d were reacted with methyltriphenylphosphoniumiodide in the presence of  
tert-BuOK in a Wittig reaction [16] to provide the styrene derivatives 3f–3h and 3k; styrene 3a–3e, 3i 
and 3j were purchased from Sigma-Aldrich (St. Louis, MO, USA) and were used without further 
purification. Iodo carboxamido was prepared in two ways (a) 2-iodoaniline was reacted with NaH and 
then acetic anhydride was added to give 2-iodoacetamide 5a; (b) A cooled solution (0–5 °C) of  
2-iodoaniline and triethylamine, was added with acyl chloride to give 5b–5f [18]. The iodo 
carboxamido 5a–5f were coupled with the styrenes 3a–3k using the Heck method by palladium (II) 
acetate catalyst to provide the (E) o-carboxamido stilbenes 6a–6s in good yield [16,17]. 
Scheme 2. Synthesis of substituted styrenes by Wittig olefination, o-carboxamido stilbenes 
by Heck coupling reaction. Reagents and conditions. (i) H3CP(C6H5)3Br, tert-BuOK, THF, 
24 h, −75 °C; (iia) NaH, acetic anhydride, DMF or (iib) triethylamine (Et3N) (0–5 °C), 
THF, acyl chloride; (iii) triethylamine (Et3N), Pd(II) acetate, 120 °C. 
 
2.2. Cytotoxic Evaluation of o-Carboxamido Stilbenes on Selected Human Cancer Cell Lines 
Resveratrol, a stilbene with antioxidant and antiproliferative properties, has been shown to inhibit  
a variety of primary tumors. However, the inhibitory effect is observed only at higher  
concentration [19,20]. In our effort to improve the cytotoxicity of resveratrol, a total of 19 resveratrol 
analogues bearing the o-carboxamido moiety were synthesized. These analogues together with  
3 standards (cisplatin, resveratrol and vinblastine) were screened against 5 human cancer cell lines and 
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one normal human cell line. Of the 19 analogues, 7 (6d, 6e, 6g–6i, 6k and 6s) were found to be 
cytotoxic toward colon cancer cell lines (HT-29), 7 (6a, 6d, 6i, 6l, 6n, 6p and 6s) toward  
estrogen-sensitive breast cancer (MCF-7), none towards estrogen-insensitive breast cancer  
(MDA-MB-231), 6 (6d, 6i–6l and 6p) toward prostate cancer (DU-145), 2 (6d and 6s) toward 
pancreatic cancer (BxPC-3) and none towards normal immortalized pancreatic cells (hTERT-HPNE). 
Analogue 6d showed cytotoxicity towards almost all cancer cell lines tested except for  
MDA-MB-231 (Table 1). Dose-response curves of the selected cytotoxic analogues toward HT-29, 
MCF-7, Bx-PC-3 and DU-145 are shown in Figure 1. 
The resveratrol analogue 6n, which has a bulky phenyl group attached to the amide and two 
methoxy group at ring B, proved the most potent against estrogen-sensitive breast cancer cell line 
(MCF-7). The analogue has an IC50 of 21.24 µM which is four times lower than that of resveratrol 
(IC50 = 85.71 µM) and comparable with that of vinblastine (IC50 = 21.00 µM). Interestingly, all the 
analogues that possess cytotoxic activity towards MCF-7 lost their inhibition when tested on  
estrogen-insensitive breast cancer (MDA-MB-231). The differences between these cancer cell lines are 
that MCF-7 possesses the estrogen receptor whereas MDA-MB-231 does not. This selective cytotoxic 
activity is also observed with resveratrol where its IC50 is 85.71 µM in MCF-7, and  
143.57 µM in MDA-MB-231. This observation is due to the similar structure of resveratrol to the 
synthetic estrogen (diethylstilbestrol) and can act as a weak competitor in binding to the estrogen 
receptors [21]. The selective cytotoxicity towards estrogen-sensitive breast cancer cell line (MCF-7) 
lead us to hypothesize that the analogues (6a, 6d, 6i, 6l, 6n, 6p and 6s) may have similar estrogen 
receptor binding properties in MCF-7. Therefore, these analogues may be potential leads for the 
development of therapeutic agents for hormone-dependent tumors. 
The structural activity relationship showed that analogues with a furan moiety at ring A and 
methoxy group at ring B have improved cytotoxicity toward the colon cancer cell line (HT-29) when 
compared with resveratrol. Almost all analogues with the furan moiety showed potent cytotoxicity, in 
particular analogue 6i (IC50 = 7.51 µM) showed ten-fold improved cytotoxicity compared with 
resveratrol (IC50 = 72.9 µM) and four-fold to cisplatin (IC50 = 30.61 µM). Significant cytotoxicity is 
also observed in the prostate cancer cell line (DU-145) with analogue 6d having an IC50 value of  
16.68 µM, which represents a six-fold increase in potency compared with resveratrol (IC50 = 107.92 µM). 
This improvement can be attributed to the acetyl group attached to the amide and fluorine, which is an 
electron withdrawing group at the meta position of the ring B in compound 6d. Together with 6d  
(IC50 = 129.78 µM), compound 6s (IC50 = 66.30 µM) having a propyl group attached to the amide, 
showed selective cytotoxic activity towards the pancreatic cancer cell line, BxPC-3, while sparing  
(IC50 > 200 µM) a normal pancreatic cell line (hTERT-HPNE). All the standards (cisplatin, vinblastine 
and resveratrol) showed no discrimination in their cytotoxicity between normal and cancer pancreatic 
cells. In chemotherapy, anticancer drugs that are selective towards cancer cells could reduce severe 
side-effects toward normal cells in the patient. Therefore, the analogues may offer an improved 
chemotherapy outcome for cancer patients compared to existing anticancer drugs. 
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3. Experimental Section 
3.1. General 
All spectral data were obtained on the following instruments: Infrared spectra were recorded on a 
Perkin Elmer FTIR Spectrum RX-1 spectrometer at wavenumber from 4000–400 cm−1. Nuclear 
magnetic resonance (NMR) spectra were obtained on a JEOL JNM-LA 400 and JEOL ECA-400. 
Spectra are reported in units of ppm on the δ scale, relative to chloroform and the coupling constants 
are given in Hz. Ultra Violet (UV) spectra were recorded from wavelength 190–400 nm, in methanol, 
on a Shimadzu UV-Visible Spectrophotometer 1650. Mass spectra were measured using Agilent 6530 
Accurate-Mass Q-TOF LC/MS system. Melting points were determined with Mel-Temp II melting 
point apparatus. 
3.2. Material 
Human cancer cell lines were obtained from American Type Culture Collection (ATCC) 
(Manassas, VA, USA). Dulbecco’s modified Eagle’s medium (DMEM), 100 mM non-essential amino 
acids, phosphate buffer solution (pH 7.2), 50 µg/mL gentamicin and 2.5 µg/mL amphotericin B were 
purchased from Invitrogen Corporation (Carlsbad, CA, USA). 200 mM L-glutamine, foetal bovine 
serum, 0.25% trypsin-EDTA, dimethyl sulphoxide (DMSO), cisplatin, resveratrol and vinblastine 
sulphate were purchased from Sigma-Aldrich (St. Louis, MO, USA). MTS [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt] assay kit (CellTiter 96
®
 
AQueous One Solution) was obtained from Promega (Madison, WI, USA). 
Figure 1. Dose-response curves of selected o-carboxamido stilbenes on human cancer cell lines. 
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Figure 1. Cont. 
  
Table 1. Cytotoxic evaluation of o-carboxamido stilbenes on human cancer cell lines. 
Entry 
IC50/µM (n = 3) 
HT-29 MCF-7 Bx-PC-3 DU-145 
Vinblastin (Positive control) 4.40 ± 2.70 21.00 ± 2.33 33.04 ± 2.14 20.31 ± 7.76 
Cisplatin (Positive control) 30.61 ± 2.34 55.04 ± 5.25 71.54 ± 5.36 22.68 ± 1.14 
Resveratrol (Control) 72.9 ± 2.4 85.71 ± 1.70 71.85 ± 1.55 107.92 ± 1.57 
6a >200 97.00 ± 4.79 >200 >200 
6b >200 >200 >200 >200 
6c >200 >200 >200 >200 
6d 11.40 ± 7.35 32.52 ± 5.16 129.78 ± 4.36 16.68 ± 1.86 
6e 15.92 ± 3.85 >200 >200 >200 
6f >200 >200 >200 >200 
6g 11.06 ± 0.27 >200 >200 >200 
6h 18.62 ± 0.56 >200 >200 >200 
6i 7.51 ± 0.53 53.32 ± 5.63 >200 29.19 ± 1.44 
6j >200 >200 >200 42.25 ± 2.02 
6k 15.60 ± 2.10 >200 >200 56.83 ± 2.37 
6l >200 115.83 ± 2.90 >200 92.79 ± 4.85 
6m >200 >200 >200 >200 
6n >200 21.24 ± 1.01 >200 >200 
6o >200 >200 >200 >200 
6p >200 128.16 ± 7.58 >200 67.89 ± 3.97 
6q >200 >200 >200 >200 
6r >200 >200 >200 >200 
6s 29.11 ± 2.73 52.04 ± 7.62 66.30 ± 1.14 >200 
3.3. Chemical 
Unless otherwise noted, materials were purchased from commercial suppliers and used without 
purification. THF was freshly distilled over calcium hydride. DMF was dried over molecular sieves 4Å 
(Sigma-Aldrich, St. Louis, MO, USA) prior to use. Column chromatography was performed using 
Merck silica gel (0.040–0.063 mm). For thin layer chromatography, Merck TLC aluminum sheets 
(silica gel 60 F254) were used; centrifugal chromatography, Merck silica gel 60 PF254 containing 
gypsum were used. 
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3.4. Procedure for the Preparation of Compounds 
3.4.1. General Procedure for Styrene 
To a suspension of methyltriphenylphosphonium iodide (1 equiv) in dry THF (25 mL), potassium 
tert-butoxide (1 equiv) was added in one portion. The mixture was stirred for 1 h at −70 °C to −80 °C. 
The appropriate aldehyde (1 equiv) was added to the solution. The ice bath was removed and the 
mixture was allowed to warm to room temperature. After consumption of starting material to form the 
product, the reaction was quenched with saturated ammonium chloride solution. The mixture was 
extracted with ethyl acetate and washed with plenty of distilled water. The resulting organic fractions 
were combined and solvent was removed under reduced pressure to yield crude product. Purification 
by column chromatography afforded the desired product. The procedure for compounds 3f, 3g, 3h and 
3k is attached in Appendix. 
1,3-methoxy-5-vinylbenzene, 3f. 
1
H NMR (CDCl3, 400 MHz) δ: 6.66 (dd, J = 17.5, 10.7 Hz, 1H), 
6.59 (d, J = 2.2 Hz, 2H), 6.41 (t, J = 2.2 Hz, 1H), 5.75 (dd, J = 17.6, 1.0 Hz, 1H), 5.26 (dd, J = 10.9, 
1.0 Hz, 1H), 3.80 (s, 6H, 2 × OCH3); 
13
C NMR (CDCl3, 100 MHz): 160.8, 139.5, 136.8, 114.2, 104.2, 
99.9, 55.1 (2 × OCH3). 
1-methoxy-2-vinylbenzene, 3g. 
1
H NMR (CDCl3, 400 MHz) δ: 7.46 (dd, J = 7.8, 1.8 Hz, 1H), 7.23 
(t, J = 7.8 Hz, 1H), 7.04 (dd, J = 17.8, 11.4 Hz, 1H), 6.93 (t, J = 7.3 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 
5.73 (dd, J = 17.8, 1.4 Hz, 1H), 5.25 (dd, J = 9.1, 1.4 Hz, 1H), 3.84 (s, 3H, OCH3); 
13
C NMR (CDCl3, 
100 MHz): 156.9, 131.9, 129.0, 126.9, 126.7, 120.8, 114.6, 111.0, 55.6. 
1-methoxy-3-vinylbenzene, 3h. 
1
H NMR (CDCl3, 400 MHz) δ: 7.26 (t, J = 8.0 Hz, 1H), 7.03 (t,  
J = 7.8 Hz, 1H), 6.98 (s, 1H), 6.83 (dd, J = 8.2 Hz, 2.8Hz, 1H), 6.71 (dd, J = 17.8 Hz, 11.0 Hz, 1H), 
5.77 (d, J = 17.8 Hz, 1H), 5.27 (d, J = 11.0 Hz, 1H), 3.83 (s, OCH3, 3H); 
13
C NMR (CDCl3,  
100 MHz): 159.9, 139.1, 136.9, 129.6, 119.1, 114.2, 113.5, 111.6, 55.3 (OCH3). 
4-vinyl-1,1'-biphenyl, 3k. 
1
H NMR (CDCl3, 400 MHz) δ: 7.60 (d, J = 6.8 Hz, 2H), 7.57 (d, J = 8.2 Hz, 
2H), 7.49 (d, J = 8.7 Hz, 2H), 7.44 (t, J = 7.5 Hz, 2H), 7.34 (t, J = 7.3 Hz, 1H), 6.76 (dd, J = 17.8,  
11.0 Hz, 1H), 5.80 (d, J = 17.8 Hz, 1H), 5.28 (d, J = 11.0 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz): 
140.9, 140.7, 136.7, 136.5, 128.9, 127.5, 127.4, 127.1, 126.8, 114.0. 
3.4.2. General Procedure for the Preparation of N-(2-iodophenyl)acylamide 
As described in [18] a solution of an appropriate acyl chloride (1 equiv) in 5 mL of dry THF was 
added dropwise to a stirred, cooled (0–5 °C) solution of 2-iodoaniline (1 equiv) and Et3N (1 equiv) in 
20 mL of dry THF. The ice bath was then removed and the mixture stirred vigorously overnight at 
room temperature. Solid Et3N∙HCl was then filtered off and washed with THF (3 × 5 mL). The 
resulting organic fractions were combined and THF was removed under reduced pressure to yield 
crude amides. Recrystallization from hexanes/chloroform and drying in vacuum produced the  
desired product. The procedure for compounds 5a–5f is attached in Appendix. 
N-(2-iodophenyl)acetamide, 5a. Mp 103–105 °C. 1H NMR (CDCl3, 400 MHz) δ: 8.17 (d, J = 7.6 Hz, 
1H), 7.75 (d, J = 7.8 Hz, 1H), 7.40 (br s, 1H, NH), 7.32 (t, J = 7.3 Hz, 1H), 6.82 (t, J = 7.4 Hz, 1H),  
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2.22 (s, 3H, CH3); 
13
C NMR (CDCl3, 100 MHz): 168.1, 138.8, 138.2, 129.2, 126.0, 122.1, 90.0,  
24.8 (CH3). 
N-(2-iodophenyl)furan-2-carboxamide, 5b. Mp 80–81 °C; IR (NaCl): 3364, 1683, 1582, 1526, 
1430, 1304, 1162, 1010, 750 cm
−1
; UV (MeOH)max nm: 257, 231; 
1
H NMR (CDCl3, 400 MHz) δ: 8.52 
(br s, 1H, NH,), 8.39 (dd, J = 8.7, 1.4 Hz, 1H), 7.80 (dd, J = 7.8, 1.4 Hz, 1H), 7.56 (d, J = 1.4 Hz, 1H), 
7.36 (td, J = 8.7, 1.4 Hz, 1H), 7.26 (d, J = 3.7 Hz, 1H), 6.85 (td, J = 7.8, 1.4 Hz, 1H), 6.57 (dd,  
J = 3.6, 1.8 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz): 156.1, 147.7, 144.8, 139.0, 138.0, 129.4, 126.1, 
121.7, 115.8, 112.8, 89.9; HRMS (+ESI) [M + H]
+
: 313.9671, C11H9INO2 requires 313.9672. 
N-(2-iodophenyl)benzamide, 5c. Mp 135–137 °C; 1H NMR (CDCl3, 400 MHz) δ: 8.46 (d, J = 8.3 Hz, 
1H), 8.30 (br s, 1H, NH), 7.96–7.98 (m, 2H), 7.82 (dd, J = 7.9, 1.5 Hz, 1H), 7.51–7.61 (m, 3H),  
7.41 (td, J = 7.8, 1.5 Hz, 1H), 6.89 (td, J = 7.7, 1.5 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz):  
165.4, 138.9, 138.4, 134.6, 132.3, 129.5, 129.0, 127.3, 126.2, 121.9, 90.3. 
N-(2-iodophenyl)cyclohexanecarboxamide, 5d. Mp 134–146 °C; 1H NMR (CDCl3, 400 MHz) δ: 
8.24 (d, J = 8.2 Hz, 1H), 7.75 (dd, J = 8.2, 1.4 Hz, 1H), 7.51 (br s, 1H, NH), 7.32 (td, J = 7.4, 1.4 Hz, 
1H), 6.82 (td, J = 7.8, 1.8 Hz, 1H), 2.30 (tt, J = 11.7, 3.4 Hz, 1H), 1.23–2.06 (m, 10H); 13C NMR 
(CDCl3, 100 MHz): 174.4, 138.8, 138.3, 129.3, 125.9, 122.1, 90.2, 46.7, 29.8 (CH2), 25.8 (CH2). 
N-(2-iodophenyl)isobutyramide, 5e. Mp 110–111 °C; 1H NMR (CDCl3, 400 MHz) δ: 8.23 (d,  
J = 8.0 Hz, 1H,), 7.75 (d, J = 8.1 Hz, 1H), 7.51 (br s, 1H, NH), 7.32 (t, J = 7.6 Hz, 1H), 6.82 (t, J = 7.3 Hz, 
1H), 2.59 (septet, J = 7.0 Hz, 1H), 1.30 (d, J = 6.8 Hz, 6H, 2 × CH3); 
13
C NMR (CDCl3, 100 MHz): 
175.3, 138.8, 138.2, 129.4, 125.9, 122.0, 90.2, 37.1, 19.7 (CH3). 
N-(2-iodophenyl)butyramide, 5f. Mp 81–83 °C; 1H NMR (CDCl3, 400 MHz) δ: 8.22 (d, J = 7.8 Hz, 
1H), 7.76 (dd, J = 8.0, 1.4 Hz, 1H), 7.43 (br s, 1H, NH,), 7.33 (td, J = 8.0, 1.4 Hz, 1H), 6.82 (t, J = 7.8 Hz, 
1H), 2.40 (d, J = 7.6 Hz, 2H), 1.79 (sextet, J = 7.8 Hz, 2H), 1.03 (t, J = 7.3 Hz, 3H, CH3); 
13
C NMR 
(CDCl3, 100 MHz): 171.3, 138.8, 138.3 , 129.4, 126.0, 122.1, 90.0, 40.0, 19.2, 13.7 (CH3). 
3.4.3. General Procedure for Stilbene 
In a dry two neck flask, the appropriate N-(2-iodophenyl)acylamide (1 equiv) was dissolved in dry 
DMF and stirred under nitrogen. The solution was heated up to 120 °C and refluxed for a few minutes. 
Palladium (II) acetate (0.01 equiv) was added, followed by triethylamine (3.5 equiv) into the mixture. 
Lastly, the appropriate styrene (1.2 equiv) was added into the reaction flask. The mixture was heated at 
120 °C under nitrogen until consumption of N-(2-iodophenyl)acylamide (check via TLC). The reaction 
mixture was quenched with saturated ammonium chloride aqueous solution. It was then extracted with 
ethyl acetate and washed with plenty of distilled water. The resulting organic fractions were combined, 
dried over anhydrous sodium sulphate and solvent was removed under reduced pressure to yield crude 
product. Purification by column chromatography afforded the desired products. The procedure for 
compounds 6a–6s is attached in Appendix. 
(E)-N-(2-(4-chlorostyryl)phenyl)acetamide, 6a [22]. Mp 201–202 °C; IR (neat): 3281, 1642, 1531, 
1299, 951, 803, 748 cm
−1
; 
1
H NMR (CDCl3, 400 MHz) δ: 7.42 (d, J = 8.3 Hz, 2H), 7.33 (d,  
J = 8.5 Hz, 2H), 6.95 (d, J = 16.0 Hz, 1H), 7.11 (d, J = 16.0 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.18 (t, 
Int. J. Mol. Sci. 2013, 14 23378 
 
 
J = 7.3 Hz, 1H), 7.52 (d, J = 7.3 Hz, 1H), 2.21 (s, 3H, CH3); 
13
C NMR (CDCl3, 100 MHz) 135.5, 
127.8, 128.9, 133.7, 128.9, 127.8, 130.9, 124.1, 130.4, 134.6, 124.7, 128.5, 125.8, 126.7, 24.2, 168.6 
(C=O); HRMS (+ESI) [M + H]
+
: 272.0873, C16H15ClNO requires 272.0842. 
(E)-N-(2-(3-chlorostyryl)phenyl)acetamide, 6b. IR (neat): 3281, 1655, 1530, 1298, 951, 773,  
749 cm
−1
; 
1
H NMR (CDCl3, 400 MHz) δ: 7.47 (br s, 1H), 7.35–7.24 (m, 4H), 6.92 (d, J = 16.0 Hz, 
1H), 7.10 (d, J = 16.0 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.18 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.8 Hz, 
1H), 2.21 (s, 3H, CH3); 
13
C NMR (CDCl3, 100 MHz) 139.0, 126.9, 134.8, 125.0, 128.8, 130.1, 130.8, 
125.1, 130.3, 134.8, 124.8, 128.1, 125.9, 126.5, 24.4 (CH3), 168.8 (C=O); HRMS (+ESI) [M + H]
+
: 
272.0800, C16H15ClNO requires 272.0842. 
(E)-N-(2-(4-fluorostyryl)phenyl)acetamide, 6c. IR (neat): 3259, 1659, 1527, 1297, 963, 818 cm
−1
; 
1
H NMR (CDCl3, 400 MHz) δ: 7.46 (d, J = 6.0 Hz, 2H), 7.01 (d, J = 8.2 Hz, 2H), 6.95 (d, J = 16.5 Hz, 
1H), 7.01–7.05 (m, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.26 (t, J = 6.8 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 
7.51 (d, J = 7.8 Hz, 1H), 2.21 (s, 3H, CH3); 
13
C NMR (CDCl3, 100 MHz) 163.7, 128.1, 115.7, 161.2, 
115.5, 128.1, 131.0, 123.2, 130.4, 134.4, 124.5, 128.2, 125.6, 126.6, 24.1 (CH3), 168.6 (C=O); HRMS 
(+ESI) [M + H]
+
: 256.1139, C16H15FNO requires 256.1138. 
(E)-N-(2-(3-fluorostyryl)phenyl)acetamide, 6d. IR (neat): 3281, 1642, 1531, 1299, 951, 803,  
748 cm
−1
; 
1
H NMR (CDCl3, 400 MHz) δ: 7.14 (br s, 1H), 6.94 (td, J = 1.4, 8.2 Hz, 1H), 7.29 (t,  
J = 7.4 Hz, 1H), 7.16–7.05 (m, 3H), 6.81 (d, J = 16.5 Hz, 1H), 7.04–7.10 (m, 1H), 7.48 (d, J = 7.8 Hz, 
1H), 7.43 (d, J = 7.8 Hz, 1H), 2.10 (s, 3H, CH3); 
13
C NMR (CDCl3, 100 MHz) 139.6, 112.9, 162.0, 
113.1, 130.2, 122.8, 130.3, 125.3, 130.4, 134.6, 124.7, 128.5, 125.8, 126.7, 24.2 (CH3), 168.6; HRMS 
(+ESI) [M + H]
+
: 256.1810, C16H15FNO requires 256.1138. 
(E)-N-(2-(4-bromostyryl)phenyl)acetamide, 6e. IR (neat): 3315, 1664, 1557, 1259, 1029, 798, 772 cm
−1
; 
1
H NMR (CDCl3, 400 MHz) δ: 7.48 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 6.91 (d,  
J = 16.5 Hz, 1H), 7.12 (d, J = 16.5 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 7.8 Hz, 1H), 7.17 (t, 
J = 7.8 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 2.19 (s, 3H, CH3); 
13
C NMR (CDCl3, 100 MHz) 136.1, 
132.0, 128.2, 121.9, 128.2, 132.0, 130.9, 124.3, 130.5, 134.7, 124.9, 128.6, 126.0, 126.8, 24.3 (CH3), 
168.9; HRMS (+ESI) [M + H]
+
: 316.0334, C16H15BrNO requires 316.0377. 
(E)-N-(2-(3,5-dimethoxystyryl)phenyl)acetamide, 6f. IR (NaCl): 3262, 1654, 1153, 773 cm
−1
. UV 
(MeOH)max nm: 305, 215; 
1
H NMR (CDCl3, 400 MHz) δ: 7.77 (d, J = 8.0 Hz, 1H), 7.49 (d J = 8.0 Hz, 
1H), 7.27 (t, J = 8.0 Hz, 1H), 7.20 (br s, 1H, NH), 7.15 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 16.1 Hz, 1H), 
6.88 (d, J = 16.1 Hz, 1H), 6.63 (d, J = 2.2 Hz, 2H), 6.41 (t, J = 2.2 Hz, 1H), 3.82 (s, 6H, OCH3), 2.19 
(s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): 168.8, 161.1, 139.1, 134.7, 132.4, 130.3, 128.4, 126.9, 
125.7, 124.4, 124.2, 105.0, 100.1, 55.4, 24.3; HRMS (+ESI) [M + H]
+
: 298.1430, C18H20NO3  
requires 298.1443. 
(E)-N-(2-(2-methoxystyryl)phenyl)furan-2-carboxamide, 6g [15]. Mp 128–129 °C; IR (NaCl): 
3285, 1671, 1585, 1304, 1247, 751 cm
−1
; UV (MeOH)max nm: 262, 321; 
1
H NMR (CDCl3, 400 MHz) 
δ: 8.25 (br s, 1H, NH), 8.04 (d, J = 8.2 Hz, 1H), 7.60 (dd, J = 7.8, 1.0 Hz, 1H), 7.56 (dd, J = 7.6,  
1.4 Hz, 1H), 7.49 (d, J = 1.0 Hz, 1H), 7.40 (d, J = 16.5 Hz, 1H), 7.29 (d, J = 16.8 Hz, 1H), 7.28–7.33 
(m, 3H), 7.20 (t, J = 7.1 Hz, 1H), 6.98 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 8.2 Hz, 1H), 6.55 (dd,  
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J = 3.7, 1.8 Hz, 1H), 3.85 (s, 3H OCH3); 
13
C NMR (CDCl3, 100 MHz): 157.3, 156.4, 148.0, 144.5, 
134.1, 130.7, 129.3, 128.3, 128.2, 127.3, 127.2, 126.2, 125.6, 123.7, 123.5, 120.9, 115.4, 112.7 , 111.1, 
55.5 (OCH3); HRMS (+ESI) [M + H]
+
: 320.1285, C20H18NO3 requires 320.1287. 
(E)-N-(2-(3-methoxystyryl)phenyl)furan-2-carboxamide, 6h [15]. Mp 96–97 °C; IR (NaCl): 3285, 
1669, 1585, 1521, 1304, 1163, 755 cm
−1
; UV (MeOH)max nm: 210, 264, 300; 
1
H NMR (CDCl3,  
400 MHz) δ: 8.17 (br s, 1H, NH), 8.02 (d, J = 8.2 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.50 (d,  
J = 1.0 Hz, 1H), 7.33 (t, J = 7.2 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.26 (d, J = 3.2 Hz, 1H), 7.22 (d,  
J = 16.0 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.12 (d, J = 7.8 Hz, 1H), 7.04 (s, 1H), 7.02 (d, J = 16.5 Hz, 
1H), 6.85 (dd, J = 8.5, 2.3 Hz, 1H), 6.56 (dd, J = 3.7, 1.8 Hz, 1H), 3.83 (s, 3H, OCH3); 
13
C NMR 
(CDCl3, 100 MHz): 160.0, 156.4, 147.9, 144.5, 138.5, 134.2, 132.9, 130.1, 129.9, 128.6, 127.3, 125.6, 
123.6, 119.4, 115.6, 113.7, 112.7, 112.3, 55.4 (OCH3); HRMS (+ESI) [M + H]
+
: 320.1282, C20H18NO3 
requires 320.1287. 
(E)-N-(2-(4-methoxystyryl)phenyl)furan-2-carboxamide, 6i [15]. Mp 120–121 °C; IR (NaCl): 3276, 
1669, 1584, 1509, 1251, 755 cm
−1
; UV (MeOH)max nm: 271, 323; 
1
H NMR (CDCl3, 400 MHz) δ: 8.17 
(br s, 1H, NH), 8.04 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.50 (d, J = 1.0 Hz, 1H), 7.47 (t,  
J = 7.6 Hz, 2H), 7.31 (td, J = 7.3, 1.3 Hz, 1H), 7.26 (d, J = 3.7 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 7.09 
(d, J = 16.5 Hz, 1H), 7.00 (d, J = 16.5 Hz, 1H), 6.92 (t, J = 7.6 Hz, 2H), 6.56 (dd, J = 3.2, 1.8 Hz, 1H), 
3.83 (s, 3H, OCH3); 
13
C NMR (CDCl3, 100 MHz): 159.8, 156.3, 148.0, 144.5, 134.0, 132.7, 130.4, 
129.9, 128.2, 128.1, 127.1, 125.6, 123.5, 121.0, 115.5, 114.3, 112.7, 55.5 (OCH3); HRMS (+ESI) [M + H]
+
: 
320.1302, C20H18NO3 requires 320.1287. 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)furan-2-carboxamide, 6j [15]. Mp 142–144 °C; IR (NaCl): 
3239, 1651, 1575, 1514, 1456, 1265, 1157, 1137, 1027, 751 cm
−1
; UV (MeOH)max nm: 210, 252, 326; 
1
H NMR (CDCl3, 400 MHz) δ: 8.19 (br s, 1H, NH), 8.00 (d, J = 8.2 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 
7.47 (dd, J = 1.8, 1.0 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.23 (d, J = 2.8 Hz, 1H), 7.18 (t, J = 7.8 Hz, 
1H), 7.07 (d, J = 16.5 Hz, 1H), 7.05 (d, J = 8.9 Hz, 1H), 7.03 (s, 1H), 6.96 (d, J = 16.5 Hz, 1H), 6.85 
(d, J = 8.2, 2.3 Hz, 1H), 6.54 (dd, J = 3.4, 1.8 Hz, 1H), 3.89 (s, 3H, OCH3), 3.88 (s, 3H, OCH3); 
13
C 
NMR (CDCl3, 100 MHz): 156.4 , 149.4, 149.2, 148.0, 144.5, 134.0, 132.7, 130.4, 130.2, 128.2, 127.1, 
125.6, 123.7, 121.4, 120.1, 115.4, 112.7, 111.4, 109.3, 56.1 (OCH3), 56.0 (OCH3); HRMS (+ESI)  
[M + H]
+
: 320.1411, C21H20NO4 requires 320.1392. 
(E)-N-(2-(3,5-dimethoxystyryl)phenyl)furan-2-carboxamide, 6k [15]. Mp 109–110 °C; IR (NaCl): 
3282, 1670, 1590, 1520, 1455, 1303, 1204, 1152, 1065, 755 cm
−1
; UV (MeOH)max nm: 239, 269, 308; 
1
H NMR (CDCl3, 400 MHz) δ: 8.16 (br s, 1H, NH), 8.04 (d, J = 7.8 Hz, 1H), 7.54 (dd,  
J = 7.8, 1.4 Hz, 1H), 7.50 (d, J = 1.0 Hz, 1H), 7.33 (td, J = 7.8, 1.4 Hz, 1H), 7.26 (d, J = 3.2 Hz, 1H), 
7.21 (d, J = 16.0 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 16.0 Hz, 1H), 6.66 (s, 2H, H-2),  
6.56 (dd, J = 3.6, 1.8 Hz, 1H), 6.43 (t, J = 1.8 Hz, 1H), 3.81 (s, 6H, 2xOCH3); 
13
C NMR (CDCl3,  
100 MHz): 161.1, 156.3, 147.9, 144.5, 139.1, 134.2, 133.0, 129.9, 128.6, 127.3, 125.6, 123.9, 123.6, 
115.6, 112.7, 105.0, 100.3, 55.9 (2 × OCH3); HRMS (+ESI) [M + H]
+
: 350.1412, C21H20NO4  
requires 350.1392. 
(E)-N-(2-(2-(biphenyl-4-yl)vinyl)phenyl)furan-2-carboxamide, 6l [15]. Mp 142–143 °C; IR (NaCl): 
3283, 1671, 1585, 1521, 1487, 1452, 1304, 762 cm
−1
; UV (MeOH)max nm: 204, 267, 323;  
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1
H NMR (CDCl3, 400 MHz) δ: 8.19 (br s, 1H, NH), 8.04 (d, J = 7.8 Hz, 1H), 7.58–7.64 (m, 7H), 7.52 
(t, J = 1.0 Hz, 1H), 7.44–7.48 (m, 2H), 7.32–7.38 (m, 2H), 7.21–7.30 (m, 3H), 7.10 (d, J = 16.5 Hz, 
1H); 
13
C NMR (CDCl3, 100 MHz): 156.4, 148.0, 144.5, 141.0, 140.6, 136.1, 134.2, 132.5, 130.2, 
129.0, 128.6, 127.6, 127.5, 127.3, 127.0, 125.7, 123.7, 123.3, 115.6, 112.7; HRMS (+ESI) [M + Na]
+
: 
388.1324, C27H22NO requires 388.1308. An X-ray of this compound was published in 2008 [23]. 
(E)-N-(2-(2-([1,1'-biphenyl]-4-yl)vinyl)phenyl)benzamide, 6m [15]. Mp 167–169 °C; IR (NaCl): 
3271, 1648, 1517, 1487, 1302, 764 cm
−1
; UV (MeOH)max nm: 319; 
1
H NMR (CDCl3, 400 MHz) δ: 
8.05 (br s, 1H, NH), 7.91 (d, J = 7.3 Hz, 3H), 7.43–7.62 (m, 12H), 7.31–7.36 (m, 2H), 7.22–7.26 (m, 
2H), 7.06 (d, J = 16.5 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz): 166.0, 140.9, 140.6, 136.1, 134.8, 134.7, 
132.2, 132.1, 131.0, 129.0, 128.5, 127.5, 127.3, 127.2, 127.1, 127.0, 126.0, 124.7, 123.5; HRMS 
(+ESI) [M + H]
+
: 376.1691, C27H22NO requires 376.1701. 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)benzamide, 6n [15]. Mp 169–171 °C; IR (NaCl): 3273, 
3012, 1646, 1572, 1509, 1265, 749 cm
−1
; UV (MeOH)max nm: 231, 324; 
1
H NMR (CDCl3, 400 MHz) 
δ: 8.03 (br s, 1H, NH), 7.87 (d, J = 7.8 Hz, 3H), 7.51–7.55 (m, 2H), 7.44 (t, J = 7.3 Hz, 2H), 7.28 (t,  
J = 7.8 Hz, 2H), 7.20 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 16.0 Hz, 1H), 6.98 (d, J = 9.2 Hz, 1H), 6.97 (s, 
1H), 6.93 (d, J = 16.0 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 3.86 (s, 3H, OCH3), 3.83 (s, 3H, OCH3);  
13
C NMR (CDCl3, 100 MHz): 166.0, 149.4, 149.2, 134.8, 134.7, 132.5, 132.0, 131.1, 130.2, 128.9, 
128.2, 127.3, 127.0, 125.9, 124.5, 121.7, 120.1, 111.3, 109.1, 56.0 (OCH3), 55.9 (OCH3); HRMS 
(+ESI) [M + H]
+
: 360.1594, C23H22NO3 requires 360.1600. 
(E)-N-(2-(4-methoxystyryl)phenyl)benzamide, 6o. IR (neat): 3283, 1644, 1512, 1482, 1248, 1178, 
1027, 749 cm
−1
; 
1
H NMR (400MHz, CDCl3) δ: 3.82 (s, 3H. OCH3), 6.87 (dt, J = 3.2, 8.7 Hz, 2H), 6.98 
(d, J = 16.0 Hz, 1H), 7.06 (d, J = 16.5 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.32 (t, J = 7.8 Hz, 1H), 7.41 
(t, J = 4.3 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.54 (t, , J = 7.3 Hz 2H), 7.89 (d, J = 7.3 Hz, 2H), 7.97 (d, 
J = 7.8 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz): 132.0, 129.0, 127.2, 134.8, 134.6, 124.1, 128.2, 125.8, 
127.1, 130.9, 121.1, 132.9, 129.8, 128.1, 114.3, 159.8, 165.5; HRMS (+ESI) [M + H]
+
: 330.1493, 
C22H20NO2 requires 330.1494. 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)cyclohexanecarboxamide, 6p [15]. Mp 204–206 °C; IR 
(NaCl): 2930, 2853, 1682, 1515, 1449, 1269, 1137, 1026, 757 cm
−1
; UV (MeOH)max nm: 217, 300;  
1
H NMR (CDCl3, 400 MHz) δ: 7.77 (d, J = 8.2 Hz, 1H), 7.50 (d, J = 7.3 Hz, 1H), 7.25 (td, J = 8.0, 1.4 Hz, 
1H), 7.21 (br s, 1H, NH), 7.17 (d, J = 7.8 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.03 (d, J = 7.3 Hz, 1H), 
7.02 (s, 1H), 6.97 (d, J = 16.5 Hz, 1H), 6.91 (d, J = 16.5 Hz, 1H), 3.91 (s, 3H, OCH3), 3.90 (s, 3H, 
OCH3), 2.31 (tt, J = 11.7, 3.4 Hz, 1H), 1.22–2.01 (m, 10H);
13
C NMR (CDCl3, 100 MHz): 174.5, 149.3, 
149.2, 134.6, 132.2, 130.8, 130.2, 128.1, 126.8, 125.6, 124.4, 121.7, 120.1, 111.3, 108.9, 56.1 (OCH3), 
55.9 (OCH3), 46.3, 29.9, 25.8; HRMS (+ESI) [M + H]
+
: 366.2069, C23H28NO3 requires 366.2069. 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)isobutyramide, 6q [15]. Mp 166–168 °C; IR (NaCl): 3274, 
1652, 1516, 1269, 1141, 1025, 961, 801, 752 cm
−1
; UV (MeOH)max nm: 210, 236, 325; 
1
H NMR 
(CDCl3, 400 MHz) δ: 7.74 (d, J = 7.8 Hz, 1H), 7.49 (d, J = 7.3 Hz, 1H), 7.31 (br s, 1H, NH), 7.24 (t,  
J = 7.8 Hz, 1H), 7.15 (t, J = 7.6 Hz, 1H), 7.01 (d, J = 7.8 Hz, 1H), 7.00 (s, 1H), 6.97 (d, J = 16.4 Hz, 
1H), 6.90 (d, J = 16.5 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 3.89 (s, 6H, 2xOCH3), 2.54–2.61 (m, 1H), 
1.27 (d, J = 6.9 Hz, 6H); 
13
C NMR (CDCl3, 100 MHz): 175.6, 149.3, 149.2, 134.6, 132.1, 130.9, 
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130.2, 128.1, 126.8, 125.7, 124.5, 121.7, 120.1, 111.3, 108.9, 56.1 (OCH3), 55.9 (OCH3), 36.5,  
19.9 (2 × CH3); HRMS (+ESI) [M + H]
+
: 326.1759, C20H24NO3 requires 326.1756. 
(E)-N-(2-(4-methoxystyryl)phenyl)isobutyramide, 6r. IR (NaCl): 3267, 2966, 1510, 1267, 1033, 
750 cm
−1
; 
1
H NMR (400MHz, CDCl3) δ: 1.27 (d, J = 6.9 Hz, 6H), 2.53–2.59 (m, 1H), 3.82 (s, 3H, 
OCH3), 7.79 (d, J = 7.8 Hz, 1H), 7.23 (td, J = 1.0, 8.0 Hz, 1H), 7.14 (d, J = 7.5 Hz, 1H), 7.48 (d,  
J = 7.8 Hz, 1H), 6.97 (d, J = 16.5 Hz, 1H), 6.92 (m, 1H), 7.41 (d, J = 9.2 Hz, 2H), 6.89 (m, 2H),  
7.33 (br s, 1H, NH); 
13
C NMR (CDCl3, 100 MHz): 19.8 (CH3), 36.5, 55.4 (OCH3), 134.6, 124.2, 
128.0, 125.5, 126.9, 130.7, 121.3, 132.0, 129.9, 128.0, 114.3, 175.5; HRMS (+ESI) [M + H]
+
: 
296.1649, C19H22NO2 requires 296.1651. 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)butyramide, 6s [15]. Mp 139–140 °C; IR (NaCl): 3280, 
2963, 1510, 1267, 1025, 759 cm
−1
; UV (MeOH)max nm: 206, 323; 
1
H NMR (CDCl3, 400 MHz) δ:  
7.63 (d, J = 7.8 Hz, 1H), 7.56 (br s, 1H, NH), 7.46 (d, J = 7.8 Hz, 1H), 7.18 (t, J = 7.0 Hz, 1H), 7.11 (t, 
J = 7.3 Hz, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.97 (s, 1H), 6.95 (d, J = 15.6 Hz, 1H), 6.85 (d,  
J = 16.2 Hz, 1H), 6.81 (d, J = 8.2 Hz, 1H), 3.86 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 2.31 (t, J = 7.3 Hz, 
2H), 1.69–1.75 (m, 2H, CH2), 0.97 (t, J = 7.3 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz): 172.0, 149.2, 
149.1, 134.6, 131.6, 131.1, 130.3, 127.9, 126.5, 125.7, 124.9, 121.8, 120.1, 111.3, 109.1, 56.0 (OCH3), 
55.9 (OCH3), 39.3, 19.4, 13.9 (CH3); HRMS (+ESI) [M + H]
+
: 326.1755, C20H24NO3 requires 326.1756. 
3.5. Cytotoxic Assays 
Cytotoxicity of the compounds were evaluated against a panel of 5 cancer cell lines; prostate  
(DU-145), pancreatic (BxPC-3), colon (HT-29), breast (MCF-7) and (MDA-MB-231); and one normal 
cell line, pancreatic (hTERT-HPNE). The cancer cell lines were chosen from the National Cancer 
Institute (NCI) list of 60 cancer cell lines for drug screening and drug treatment conditions adhered to 
NCI recommendations [24]. 
Cell lines were cultured in DMEM media supplemented with 2 mM L-glutamine, 10% foetal bovine 
serum, 50 µg/mL gentamicin and 2.5 µg/mL amphotericin B, maintained in a 37 °C humid atmosphere 
of 5% CO2 cell incubator. hTERT-HPNE cell line was cultured in the same DMEM with 10 ng/mL 
human recombinant epithelial growth factor as recommended by ATCC. Samples and drug standards 
(cisplatin, resveratrol and vinblastine) were dissolved in DMSO and immediately diluted with DMEM 
media to yield a final DMSO concentration of less than 0.5% v/v. 
Cells were plated into 96-well microplates at 5000–10,000 cells per well and maintained in the cell 
incubator for 24 h. Then, 100 µL of samples were introduced in triplicates to a final concentration of 
0.1–200 µM. Drug standards were also introduced to a final concentration of 0.03–2000 µM (cisplatin) 
0.78–400 µM (resveratrol) and 0.002–200 µM (vinblastine). Cells were further incubated for 48 h and 
then, cell viability was determined according to the manufacturer protocol of a commercial MTS assay 
kit (CellTiter 96
®
 AQueous One Solution, Promega). Culture media were carefully refreshed with  
100 µL of DMEM media, followed by 20 µL per well of MTS reagent. Microplates were returned to 
the incubator for 1–2 h and absorbance of the formazan product was read on a microplate reader at  
490 nm with 690 nm as the background wavelength (Infinite 200, Tecan, Mannedorf, Swizerland). 
IC50 of samples and drug standards were determined using dose-response curves, and statistical 
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analysis using student’s T-test (p < 0.05) was performed in Prism 5.02 software (GraphPad Software Inc., 
La Jolla, CA, USA). 
4. Conclusions 
A total of 19 analogues of o-carboxamido stilbenes were synthesized using the Heck method. These 
analogues possessing the amide moiety with different substituent groups displayed varying cytotoxic 
activity toward various human cancer cell lines with the most potent compounds; compound 6d  
(IC50 = 16.68 µM, prostate cancer DU-145), compound 6i (IC50 = 7.51 µM, colon cancer HT-29), 
compound 6n (IC50 = 21.24 µM, estrogen-sensitive breast cancer MCF-7) and compound 6s  
(IC50 = 66.30 µM, pancreatic cancer BxPC-3). Interestingly, all these potent compounds did not show 
any cytotoxicity toward the normal pancreatic cell line (hTERT-HPNE) compared to vinblastine, cisplastin 
and resveratrol which exhibited cytotoxicity toward the normal pancreatic cell line (hTERT-HPNE). These 
results provide progress in our knowledge to support future designs of stilbene-based anticancer drugs. 
Acknowledgments 
We are grateful to the University of Malaya Postgraduate Research Grant (PPP) (PV090/2011A) 
and (PV050/2012A), the Ministry of Higher Education (MOHE) Fundamental Research Grant Scheme 
(2010-0063-101-02), University of Malaya Research Grant (UMRG) (RP001/2012B) and ScienceFund 
(SF018-2013) for the financial supports. 
Conflicts of Interest 
The authors declare no conflict of interest. 
Appendix 
Experimental Data 
1,3-methoxy-5-vinylbenzene, 3f. 3,5-methoxybenzaldehyde 2a (5.00 g, 30.09 mmol) was treated 
with methyltriphenylphosphonium iodide (12.37 g, 30.61 mmol) and potassium tert-butoxide (3.41 g, 
30.35 mmol) according to the general procedure. Purification by column chromatography 
(hexane/ethyl acetate, 98:2) afforded the product as colourless oil. Yield: 2.68 g (54%). 
1-methoxy-2-vinylbenzene, 3g. 2-methoxybenzaldehyde 2b (5.04 g, 37.00 mmol) was treated with 
methyltriphenylphosphonium iodide (14.84 g, 36.72 mmol) and potassium tert-butoxide (4.13 g,  
36.82 mmol) according to the general procedure. Purification by column chromatography 
(hexane/ethyl acetate, 98:2) afforded the product as colourless oil. Yield: 2.82 g (57%). 
1-methoxy-3-vinylbenzene, 3h. 3-methoxybenzaldehyde 2c (5.04 g, 36.76 mmol) was treated with 
methyltriphenylphosphonium iodide (14.92 g, 36.91 mmol) and potassium tert-butoxide (4.24 g,  
37.79 mmol) according to the general procedure. Purification by column chromatography 
(hexane/ethyl acetate, 98:2) afforded the product as colourless oil. Yield: 2.95 g (60 (%). 
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4-vinyl-1,1'-biphenyl, 3k. Biphenyl-4-carbaldehyde 2d (0.99 g, 5.44 mmol) was treated with 
methyltriphenylphosphonium iodide (2.25 g, 5.56 mmol) and potassium tert-butoxide (0.62 g,  
5.50 mmol) according to the general procedure. Purification by column chromatography  
(hexane/ethyl acetate, 98:2) afforded the product as white solid. Yield: 0.54 g (55%). 
N-(2-iodophenyl)acetamide, 5a. To a stirred, cooled (0–5 °C) solution of 2-iodoaniline (2.53 g, 
11.57 mmol) in 20 mL of dry DMF, sodium hydride (0.92 g, 23.14 mmol) and acetic anhydride  
(5.40 mL, 61.75 mmol) was added into the reaction flask. Then ice bath was removed and the mixture 
was allowed to stir overnight at room temperature. Saturated ammonium chloride was added to the 
reaction mixture followed by extraction with ethyl acetate. The combined ethyl acetate extracts were 
then washed with distilled water to remove DMF. The solution was then filtered and dried over 
anhydrous sodium sulphate. The crude product, obtained after evaporation under reduced pressure was 
purified by column chromatography to give the purified product as yellowish solid. Yield: 1.82 g (60%). 
N-(2-iodophenyl)furan-2-carboxamide, 5b. 2-iodoaniline (5.48 g, 25.03 mmol) was treated with 
furan-2-carbonyl chloride (2.5 mL, 25.40 mmol) according to the general procedure. The crude 
product was purified by column chromatography (hexane/ethyl acetate, 90:10) to give a yellowish 
solid. Yield: 5.49 g (69%). 
N-(2-iodophenyl)benzamide, 5c [18]. 2-iodoaniline (5.49 g, 25.05 mmol) was treated with benzoyl 
chloride (2.9 mL, 24.98 mmol) according to the general procedure. Recrystalization of the crude 
product from hexanes/CHCl3 afforded a yellowish solid. Yield: 6.55 g (81%). 
N-(2-iodophenyl)cyclohexanecarboxamide, 5d [18]. 2-iodoaniline (5.50 g, 25.11 mmol) was treated 
with cyclohexanecarbonyl chloride (3.4 mL, 25.04 mmol) according to the general procedure. 
Recrystalization of the crude product from hexanes/CHCl3 afforded an off-white solid. Yield:  
6.13 g (74%). 
N-(2-iodophenyl)isobutyramide, 5e [18]. 2-iodoaniline (5.49 g, 25.06 mmol) was treated with 
isobutyryl chloride (2.70 mL, 25.59 mmol) according to the general procedure. Recrystalization of the 
crude product from hexanes/CHCl3 afforded an off-white solid. Yield: 5.46 g (75%). 
N-(2-iodophenyl)butyramide, 5f [18]. 2-iodoaniline (2.19 g, 10.01 mmol) was treated with butyryl 
chloride (1.0 mL, 10.26 mmol) according to the general procedure. Recrystalization of the crude 
product from hexanes/CHCl3 afforded an off-white solid. Yield: 2.00 g (69%). 
(E)-N-(2-(4-chlorostyryl)phenyl)acetamide, 6a [22]. Compound 5a (0.30 g, 1.15 mmol) was 
dissolved in 50 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (2.6 mg, 0.0115 mmol) was added, followed by triethylamine  
(0.48 mL, 3.45 mmol) into the mixture. Compound 3a (0.20 g, 1.37 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5a (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (dichloromethane/ethyl acetate, 97:3) afforded an off-white solid. Yield:  
0.11 g (35%). 
(E)-N-(2-(3-chlorostyryl)phenyl)acetamide, 6b. Compound 5a (0.30 g, 1.15 mmol) was dissolved in 
50 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a few minutes. 
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Palladium (II) acetate (2.6 mg, 0.0115 mmol) was added, followed by triethylamine  
(0.48 mL, 3.45 mmol) into the mixture. Compound 3b (0.17 g, 1.20 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5a (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (dichloromethane/ethyl acetate, 97:3) afforded an off-white solid. Yield:  
0.09 g (27%). 
(E)-N-(2-(4-fluorostyryl)phenyl)acetamide, 6c. Compound 5a (0.30 g, 1.15 mmol) was dissolved in 
50 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a few minutes. 
Palladium (II) acetate (2.6 mg, 0.0115 mmol) was added, followed by triethylamine  
(0.48 mL, 3.45 mmol) into the mixture. Compound 3c (0.15 g, 1.20 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5a (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (dichloromethane/ethyl acetate, 97:3) afforded an off-white solid. Yield:  
0.13 g (42%). 
(E)-N-(2-(3-fluorostyryl)phenyl)acetamide, 6d. Compound 5a (1.0 g, 3.83 mmol) was dissolved in 
20 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a few minutes. 
Palladium (II) acetate (17.2 mg, 0.0767 mmol) was added, followed by triethylamine  
(1.9 mL, 13.41 mmol) into the mixture. Compound 3d (0.49 g, 4.00 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5a (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (dichloromethane/ethyl acetate, 97:3) afforded an off-white solid. Yield:  
0.20 g (20%). 
(E)-N-(2-(4-bromostyryl)phenyl)acetamide, 6e. Compound 5a (0.30 g, 1.15 mmol) was dissolved in 
80 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a few minutes. 
Palladium (II) acetate (2.6 mg, 0.0115 mmol) was added, followed by triethylamine (0.7 mL,  
4.6 mmol) into the mixture. Compound 3e (0.2288 g, 1.25 mmol) was added into the reaction flask. 
The mixture was reflux under nitrogen until consumption of compound 5a (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (dichloromethane/ethyl acetate, 97:3) afforded a yellow solid. Yield:  
0.13 g (37%). 
(E)-N-(2-(3,5-dimethoxystyryl)phenyl)acetamide, 6f. Compound 5a (1.02 g, 3.93 mmol) was 
dissolved in 10 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (16.5 mg, 0.0735 mmol) was added, followed by triethylamine 
(1.94 mL, 13.9 mmol) into the mixture. Compound 3f (0.78g, 4.77 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5a (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 60:40) afforded an off-white solid. Yield: 0.52 g (45%). 
(E)-N-(2-(2-methoxystyryl)phenyl)furan-2-carboxamide, 6g [15]. Compound 5b (1.51 g, 4.81 mmol) was 
dissolved in 25 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (11.2 mg, 0.0499 mmol) was added, followed by triethylamine  
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(2.4 mL, 17.22 mmol) into the mixture. Compound 3g (0.83 g, 6.16 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5b (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 60:40) afforded a white solid. Yield: 0.75 g (49%). 
(E)-N-(2-(3-methoxystyryl)phenyl)furan-2-carboxamide, 6h [15]. Compound 5b (0.44 g, 1.41 mmol) was 
dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (3.6 mg, 0.0160 mmol) was added, followed by triethylamine  
(0.8 mL, 5.74 mmol) into the mixture. Compound 3h (0.30 g, 2.24 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5b (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 60:40) afforded a white solid. Yield: 0.15 g (33%). 
(E)-N-(2-(4-methoxystyryl)phenyl)furan-2-carboxamide, 6i [15]. Compound 5b (0.52 g, 1.65 mmol) was 
dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (3.6 mg, 0.0160 mmol) was added, followed by triethylamine  
(0.8 mL, 5.74 mmol) into the mixture. Compound 3i (0.32 g, 2.39 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5b (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 60:40) afforded a white solid. Yield: 0.19 g (36%). 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)furan-2-carboxamide, 6j [15]. Compound 5b (0.57 g,  
1.83 mmol) was dissolved in 25 mL dry DMF. The solution was heated up to 120 °C and refluxed 
under nitrogen for a few minutes. Palladium (II) acetate (5.2 mg, 0.0232 mmol) was added, followed 
by triethylamine (1.2 mL, 8.61 mmol) into the mixture. Compound 3j (0.35 g, 2.14 mmol) was added 
into the reaction flask. The mixture was reflux under nitrogen until consumption of compound 5b 
(check via TLC). The reaction mixture was treated according to the general procedure. Purification of 
the crude product by column chromatography (hexane/ethyl acetate, 60:40) afforded a white solid. 
Yield: 0.10 g (16%). 
(E)-N-(2-(3,5-dimethoxystyryl)phenyl)furan-2-carboxamide, 6k [15]. Compound 5b (0.57 g,  
1.83 mmol) was dissolved in 25 mL dry DMF. The solution was heated up to 120 °C and refluxed 
under nitrogen for a few minutes. Palladium (II) acetate (5.2 mg, 0.0232 mmol) was added, followed 
by triethylamine (1.2 mL, 8.61 mmol) into the mixture. Compound 3f (0.35 g, 2.14 mmol) was added 
into the reaction flask. The mixture was reflux under nitrogen until consumption of compound 5b 
(check via TLC). The reaction mixture was treated according to the general procedure. Purification of 
the crude product by column chromatography (hexane/ethyl acetate, 60:40) afforded a white solid. 
Yield: 0.10 g (17%). 
(E)-N-(2-(2-(biphenyl-4-yl)vinyl)phenyl)furan-2-carboxamide, 6l [15]. Compound 5b (0.37 g,  
1.18 mmol) was dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed 
under nitrogen for a few minutes. Palladium (II) acetate (3.2 mg, 0.0143 mmol) was added, followed 
by triethylamine (0.7 mL, 4.66 mmol) into the mixture. Compound 3k (0.20 g, 1.21 mmol) was added 
into the reaction flask. The mixture was reflux under nitrogen until consumption of compound 5b 
(check via TLC). The reaction mixture was treated according to the general procedure. Purification of 
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the crude product by column chromatography (hexane/ethyl acetate, 90:10) afforded a yellowish solid. 
Yield: 0.04 g (9%). 
(E)-N-(2-(2-([1,1'-biphenyl]-4-yl)vinyl)phenyl)benzamide, 6m [15]. Compound 5c (0.17 g,  
0.5106 mmol) was dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed 
under nitrogen for a few minutes. Palladium (II) acetate (2.5 mg, 0.0111 mmol) was added, followed 
by triethylamine (1.0 mL, 7.17 mmol) into the mixture. Compound 3k (0.10 g, 0.5570 mmol) was 
added into the reaction flask. The mixture was reflux under nitrogen until consumption of compound 
5c (check via TLC). The reaction mixture was treated according to the general procedure. Purification 
of the crude product by column chromatography (hexane/ethyl acetate, 90:10) afforded a white solid. 
Yield: 0.06 g (31%). 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)benzamide, 6n [15]. Compound 5c (0.51 g, 1.58 mmol) was 
dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (3.5 mg, 0.0156 mmol) was added, followed by triethylamine  
(0.8 mL, 5.74 mmol) into the mixture. Compound 3j (0.37 g, 2.24 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5c (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 80:20) afforded a white solid. Yield: 0.10 g (18%). 
(E)-N-(2-(4-methoxystyryl)phenyl)benzamide, 6o. Compound 5c (0.51 g, 1.58 mmol) was 
dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (3.5 mg, 0.0156 mmol) was added, followed by triethylamine  
(0.8 mL, 5.74 mmol) into the mixture. Compound 3i (0.32 g, 2.39 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5c (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 80:20) afforded a white solid. Yield: 0.15 g (28%). 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)cyclohexanecarboxamide, 6p [15]. Compound 5d (0.21 g, 
0.63 mmol) was dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed 
under nitrogen for a few minutes. Palladium (II) acetate (2.1 mg, 0.0094 mmol) was added, followed 
by triethylamine (0.5 mL, 3.59 mmol) into the mixture. Compound 3j (0.15 g, 0.93 mmol) was added 
into the reaction flask. The mixture was reflux under nitrogen until consumption of compound 5d 
(check via TLC). The reaction mixture was treated according to the general procedure. Purification of 
the crude product by column chromatography (hexane/ethyl acetate, 80:20) afforded a white solid. 
Yield: 0.07 g (31%). 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)isobutyramide, 6q [15]. Compound 5e (1.49 g, 5.16 mmol) was 
dissolved in 25 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (11.9 mg, 0.053 mmol) was added, followed by triethylamine  
(2.8 mL, 20.09 mmol) into the mixture. Compound 3j (1.02 g, 6.23 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5e (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 80:20) afforded an off-white solid. Yield: 0.4505 g (27%). 
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(E)-N-(2-(4-methoxystyryl)phenyl)isobutyramide, 6r. Compound 5e (0.31 g, 1.09 mmol) was 
dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (2.4 mg, 0.0011 mmol) was added, followed by triethylamine  
(0.6 mL, 4.30 mmol) into the mixture. Compound 3i (0.22 g, 1.37 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5e (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 80:20) afforded an off-white solid. Yield: 0.05 g (14%). 
(E)-N-(2-(3,4-dimethoxystyryl)phenyl)butyramide, 6s [15]. Compound 5f (0.31 g, 1.09 mmol) was 
dissolved in 20 mL dry DMF. The solution was heated up to 120 °C and refluxed under nitrogen for a 
few minutes. Palladium (II) acetate (2.4 mg, 0.0011 mmol) was added, followed by triethylamine  
(0.6 mL, 4.30 mmol) into the mixture. Compound 3j (0.22 g, 1.37 mmol) was added into the reaction 
flask. The mixture was reflux under nitrogen until consumption of compound 5f (check via TLC). The 
reaction mixture was treated according to the general procedure. Purification of the crude product by 
column chromatography (hexane/ethyl acetate, 80:20) afforded an off-white solid. Yield: 0.05 g (15%). 
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